APG Asset Management US Inc. Has $516,000 Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

APG Asset Management US Inc. reduced its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 10.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 23,412 shares of the company’s stock after selling 2,612 shares during the quarter. APG Asset Management US Inc.’s holdings in Teva Pharmaceutical Industries were worth $516,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Oarsman Capital Inc. acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter worth approximately $29,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Teva Pharmaceutical Industries during the third quarter valued at approximately $50,000. Ameliora Wealth Management Ltd. bought a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at $66,000. IFP Advisors Inc grew its position in Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock valued at $88,000 after acquiring an additional 1,960 shares during the period. Finally, Quadrant Capital Group LLC grew its position in Teva Pharmaceutical Industries by 27.7% in the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company’s stock valued at $96,000 after acquiring an additional 949 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TEVA has been the topic of a number of recent analyst reports. UBS Group reduced their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Friday, April 4th. Bank of America lowered their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, March 6th. Barclays lowered their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. Finally, Piper Sandler increased their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $23.43.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $14.17 on Thursday. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80. The stock has a market capitalization of $16.06 billion, a PE ratio of -9.77, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. The stock has a 50 day moving average price of $15.95 and a 200 day moving average price of $17.88. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.